Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Debt (2017 - 2024)

United Therapeutics' Non-Current Debt history spans 13 years, with the latest figure at $100.0 million for Q2 2024.

  • For Q2 2024, Non-Current Debt fell 87.5% year-over-year to $100.0 million; the TTM value through Jun 2024 reached $100.0 million, down 87.5%, while the annual FY2023 figure was $300.0 million, 62.5% down from the prior year.
  • Non-Current Debt for Q2 2024 was $100.0 million at United Therapeutics, down from $200.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $800.0 million in Q1 2020 and bottomed at $100.0 million in Q2 2024.
  • The 5-year median for Non-Current Debt is $800.0 million (2020), against an average of $683.3 million.
  • The largest annual shift saw Non-Current Debt surged 33.33% in 2020 before it plummeted 87.5% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then plummeted by 62.5% to $300.0 million in 2023, then crashed by 66.67% to $100.0 million in 2024.
  • Per Business Quant, the three most recent readings for UTHR's Non-Current Debt are $100.0 million (Q2 2024), $200.0 million (Q1 2024), and $300.0 million (Q4 2023).